Holen Sie sich die Stockscreener-App
0.9298
3.43%
0.0308
Schlusskurs vom Vortag:
$0.899
Offen:
$0.899
24-Stunden-Volumen:
39,146
Relative Volume:
0.99
Marktkapitalisierung:
$38.02M
Einnahmen:
$13.42M
Nettoeinkommen (Verlust:
$-73.35M
KGV:
-
EPS:
-
Netto-Cashflow:
$-56.34M
1W Leistung:
-32.62%
1M Leistung:
-30.27%
6M Leistung:
-56.78%
1J Leistung:
-65.82%
1-Tages-Spanne:
$0.899
$0.99
1-Wochen-Bereich:
$0.81
$1.38
52-Wochen-Spanne:
$0.81
$4.1591
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Firmenname
Barinthus Biotherapeutics Plc Adr
Sektor
Branche
Telefon
44 (0) 1865 818808
Adresse
UNIT 6-10, ZEUS BUILDING, DIDCOT
Vergleichen Sie BRNS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BRNS | 0.989 | 38.02M | 13.42M | -73.35M | -56.34M | 0.00 |
| VRTX | 450.01 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.02 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.85 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.66 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Barinthus Biotherapeutics Plc Adr Aktie (BRNS) Neueste Nachrichten
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ... - Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket By ... - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Barinthus Bio refocuses on hepatitis B and celiac disease treatments By Investing.com - Investing.com
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewswire Inc.
Market Update: Barinthus Biotherapeutics Plc. ADR (BRNS) Sees Negative Movement, Closing at 2.00 – DWinneX - The Dwinnex
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 - Investing.com India
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates - Zacks Investment Research
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
ANVS Stock Quote Price and Forecast - CNN
TPST Stock Quote Price and Forecast - CNN
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Finanzdaten der Barinthus Biotherapeutics Plc Adr-Aktie (BRNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):